Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04040725
Title Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

bladder urothelial carcinoma

Therapies

Rogaratinib

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST